We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Determine the Safety and Efficacy of (R,R)-Formoterol in the Treatment of Subjects With COPD

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00064402
First Posted: July 9, 2003
Last Update Posted: February 22, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Sunovion
  Purpose
The purpose of this study is to assess the bronchodilator effect and safety of multiple daily doses of arformoterol administered for 12 weeks as maintenance treatment in patients with COPD

Condition Intervention Phase
Chronic Obstructive Pulmonary Disease Chronic Bronchitis Emphysema Drug: arformoterol tartrate inhalation solution Drug: Salmeterol Drug: Placebo Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Double-Blind, Double-Dummy, Randomized, Placebo- and Active-Controlled, Multicenter, Parallel-Group Study of (R,R)-Formoterol in the Treatment of Subjects With Chronic Obstructive Pulmonary Disease

Resource links provided by NLM:


Further study details as provided by Sunovion:

Primary Outcome Measures:
  • percent change in trough FEV1 from study baseline to the end of the dosing interval (12 hours post-second dose for the BID treatment arms and 24 hours postdose for the QD treatment arm) over the double-blind period. [ Time Frame: Weeks -2, 0, 3, 6, 9, 12 ]

Secondary Outcome Measures:
  • time-normalized area under the percent change from visit predose curve for FEV1 over 12 hours (nAUC0-12-P) [ Time Frame: Weeks -2, 0, 3, 6, 9, 12 ]
  • Peak percent of predicted FEV1 [ Time Frame: Weeks -2, 0, 3, 6, 9, 12 ]
  • time-normalized area under the percent change in FEV1 from study baseline over 12 hours (nAUC0-12-B) [ Time Frame: Weeks -2, 0, 3, 6, 9, 12 ]
  • time-normalized area under the percent change from visit predose curve for FEV1 over 24 hours (nAUC0-24-P) [ Time Frame: Weeks -2, 0, 3, 6, 9, 12 ]
  • time-normalized area under the percent change in FEV1 from study baseline curve over 24 hours (nAUC0-24-B) [ Time Frame: Weeks -2, 0, 3, 6, 9, 12 ]
  • peak percent change in FEV1 from visit predose and study baseline [ Time Frame: Weeks -2, 0, 3, 6, 9, 12 ]
  • time point changes in FEV1; time to onset of response [ Time Frame: Weeks -2, 0, 3, 6, 9, 12 ]
  • time to peak change in FEV1 [ Time Frame: Weeks -2, 0, 3, 6, 9, 12 ]
  • at-home and in-clinic peak expiratory flow rate (PEFR) [ Time Frame: Weeks -2, 0, 3, 6, 9, 12 ]
  • relationship between the plasma concentration values and selected pharmacodynamic parameters [ Time Frame: Weeks -2, 0, 3, 6, 9, 12, 13 ]
  • Supplemental ipratropium bromide MDI and racemic albuterol MDI use [ Time Frame: Weeks 0-13 ]
  • COPD exacerbations and COPD symptom ratings [ Time Frame: Weeks 0-13 ]
  • St. George's Hospital Respiratory Questionnaire [ Time Frame: Weeks 0, 6, 13 ]
  • Investigator and Subject Global Evaluations [ Time Frame: Weeks -2, 12, 13 ]
  • Baseline and Transitional Dyspnea Index [ Time Frame: Weeks -2, 6, 12 ]
  • distance walked in six minutes [ Time Frame: Weeks -2, 3, 9 ]

Enrollment: 741
Study Start Date: April 2002
Study Completion Date: March 2004
Primary Completion Date: March 2004 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Arformoterol 50 mcg QD and placebo MDI
Drug: arformoterol tartrate inhalation solution
arformoterol 50 mcg QD
Other Name: (R,R)-formoterol
Experimental: 2
Arformoterol 25 mcg BID and Placebo MDI
Drug: arformoterol tartrate inhalation solution
arformoterol 25 mcg BID
Other Name: (R,R)-formoterol
Experimental: 3
Arformoterol 15 mcg BID and placebo MDI
Drug: arformoterol tartrate inhalation solution
arformoterol 15 mcg BID
Other Names:
  • (R,R)-formoterol
  • Brovana
Active Comparator: 4
Salmeterol MDI 42 mcg BID and placebo inhalation solution
Drug: Salmeterol
Salmeterol MDI 42 mcg BID
Other Name: Serevent MDI
Placebo Comparator: 5
Placebo MDI and placebo inhalation solution
Drug: Placebo
Placebo BID

Detailed Description:
This was a double-blind, double-dummy, randomized, placebo- and active-controlled, multicenter, parallel-group study of adult subjects with COPD. The study was double blinded through the use of both unit dose vial (UDV) and metered-dose inhaler (MDI) placebos, as appropriate. The primary efficacy analysis utilized the placebo control. Secondary analyses of the primary efficacy endpoint utilized the active control, and included comparisons between the placebo and active control. This study was previously posted by Sepracor Inc. In October 2009, Sepracor Inc. was acquired by Dainippon Sumitomo Pharma., and in October 2010, Sepracor Inc's name was changed to Sunovion Pharmaceuticals Inc.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   35 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Be willing to comply with study procedures and visit schedule
  • Are at least 35 years of age
  • Female subjects >65 years of age must have a serum pregnancy test conducted at Visit 1 and confirmed negative prior to randomization
  • Subjects of childbearing potential must be using an acceptable method of birth control. Female subjects who are considered not of childbearing potential must be: documented surgically sterile, OR postmenopausal.
  • Have a primary diagnosis of COPD. Diagnosis can be made during the screening process.
  • Have a minimum smoking history of 15 pack-years (pack-years = the number of cigarette packs per day times the number of years).
  • Have a chest x-ray that is consistent with the diagnosis of COPD and taken <3 months prior to study start
  • Able to complete all study questionnaires and logs reliably

Exclusion Criteria:

  • Female subject who is pregnant or lactating
  • Have participated in an investigational drug study within 30 days prior to study start, or who is currently participating in another investigational drug study
  • Subject whose schedule or travel prevents the completion of all required visits
  • Are scheduled for in-patient hospitalization, including elective surgery during the trial
  • Have life-threatening/unstable respiratory status, including upper or lower respiratory tract infection, within the previous 30 days
  • History of asthma or any chronic respiratory disease other than COPD (chronic bronchitis and/or emphysema)
  • Have clinically significant cardiac, hepatic, renal, gastrointestinal, endocrine, metabolic, neurologic, or psychiatric disorder that may interfere with successful completion of this protocol
  • Have a history of cancer except non-melanomatous skin cancer
  • Have a history of lung resection of more than one full lobe
  • Requires continuous supplemental oxygen therapy.
  • Has had a change in dose or type of any medications for COPD within 14 days prior to the screening visit
  • Have a known sensitivity to arformoterol, ipratropium, salmeterol or albuterol or any of the excipients contained in any of these formulations
  • Have a history of substance abuse or drug abuse within 12 months, or with a positive urine drug screen
  • Are using any prescription drug for which concomitant beta-agonist administration is contraindicated (e.g., beta-blockers)
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00064402


  Show 65 Study Locations
Sponsors and Collaborators
Sunovion
  More Information

Responsible Party: Sunovion
ClinicalTrials.gov Identifier: NCT00064402     History of Changes
Other Study ID Numbers: 091-051
First Submitted: July 8, 2003
First Posted: July 9, 2003
Last Update Posted: February 22, 2012
Last Verified: February 2012

Additional relevant MeSH terms:
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Emphysema
Bronchitis
Bronchitis, Chronic
Respiratory Tract Diseases
Pathologic Processes
Bronchial Diseases
Respiratory Tract Infections
Pharmaceutical Solutions
Formoterol Fumarate
Salmeterol Xinafoate
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Adrenergic beta-2 Receptor Agonists
Adrenergic beta-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action